Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter

Cancer Research

Volumn 72, Issue 14, 2012, Pages 3642-3651

  Basseville, Agnes ^a   Tamaki, Akina ^a   Ierano, Caterina ^a   Trostel, Shana ^a   Ward, Yvona ^a   Robey, Robert W ^a   Hegde, Ramanujan S ^b   Bates, Susan E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NICHHD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYCLOHEXIMIDE; HISTONE DEACETYLASE INHIBITOR; MITOXANTRONE; PANOBINOSTAT; ROMIDEPSIN; VALPROIC ACID; VORINOSTAT;

AGGRESOME; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CLEARANCE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MICROTUBULE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN POLYMORPHISM; PROTEIN PROCESSING; PROTEIN SYNTHESIS; PROTEIN TARGETING; PROTEIN TRANSPORT; TRANSCRIPTION REGULATION; UBIQUITINATION;

ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL LINE; GENE EXPRESSION; HISTONE DEACETYLASE INHIBITORS; HUMANS; MITOXANTRONE; NEOPLASM PROTEINS; POLYMORPHISM, GENETIC; RNA, SMALL INTERFERING;

EID: 84863883943     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2008     Document Type: Article

References (41)

1. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001;42:1007-17. (Pubitemid 32645780)
2. Ozvegy C, Litman T, Szakács G, Nagy Z, Bates S, Váradi A, et al. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun 2001;285:111-7. (Pubitemid 32912517)
3. Robey RW,To KK, Polgar O, Dohse M, Fetsch P, Dean M, et al. ABCG2: a perspective. Adv Drug Deliv Rev 2009;61:3-13.
4. van Herwaarden AE, Jonker JW, Wagenaar E, Brinkhuis RF, Schellens JH, Beijnen JH, et al. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl- 6-phenylimidazo[4,5-b] pyridine. Cancer Res 2003;63:6447-52. (Pubitemid 37255195)
5. van Herwaarden AE, Wagenaar E, Karnekamp B, Merino G, Jonker JW, Schinkel AH. Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis 2006;27:123-30. (Pubitemid 43025252)
6. Ni Z, Bikadi Z, Rosenberg MF, Mao Q. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab 2010;11:603-17.
7. Dehghan A, Kottgen A, Yang Q, Hwang SJ, Kao WL, Rivadeneira F, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 2008;372:1953-61.
8. Loo TW, Bartlett MC, Clarke DM. Rescue of folding defects in ABC transporters using pharmacological chaperones. J Bioenerg Biomembr 2005;37:501-7. (Pubitemid 43725183)
9. Pedemonte N, Sonawane ND, Taddei A, Hu J, Zegarra-Moran O, Suen YF, et al. Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 2005;67:1797-807. (Pubitemid 40594181)
10. Wang Y, Loo TW, Bartlett MC, Clarke DM. Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones. Mol Pharmacol 2007;71:751-8. (Pubitemid 46294086)
11. Loo TW, Bartlett MC, Clarke DM. Correctors promote folding of the CFTR in the endoplasmic reticulum. Biochem J 2008;413:29-36. (Pubitemid 351946859)
12. Polgar O, Ierano C, Tamaki A, Stanley B, Ward Y, Xia D, et al. Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2. Biochemistry 2010;49:2235-45.
13. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84. (Pubitemid 44348499)
14. Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 2009;69:1911-34.
15. Mizuarai S, Aozasa N, Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 2004;109:238-46. (Pubitemid 38240926)
16. Morisaki K, Robey R, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K, et al. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 2005;56:161-72. (Pubitemid 40884271)
17. Furukawa T, Wakabayashi K, Tamura A, Nakagawa H, Morishima Y, Osawa Y, et al. Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations. Pharm Res 2009;26:469-79.
18. Turnbull EL, Rosser MF, Cyr DM. The role of the UPS in cystic fibrosis. BMC Biochem 2007;8:Suppl 1:S11.
19. Diop N, Hrycyna C. N-linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasmamembrane. Biochemistry 2005;44:5420-9. (Pubitemid 40489981)
20. Prescott AR, Lucocq JM, James J, Lister JM, Ponnambalam S. Distinct compartmentalization of TGN46 and beta 1,4-galactosyltransferase in HeLa cells. Eur J Cell Biol 1997;72:238-46. (Pubitemid 27117130)
21. Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998;143:1883-98. (Pubitemid 29022611)
22. Zheng Y, Jung MK, Oakley BR.Gamma-tubulin is present in Drosophila melanogaster and Homo sapiens and is associated with the centrosome. Cell 1991;65:817-23. (Pubitemid 121001313)
23. To K, Polgar O, Huff L, Morisaki K, Bates S. Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol Cancer Res 2008;6:151-64. (Pubitemid 351378175)
24. To KK, Robey R, Zhan Z, Bangiolo L, Bates SE. Upregulation of ABCG2 by romidepsin via the aryl hydrocarbon receptor pathway. Mol Cancer Res 2011;9:516-27.
25. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003;115:727-38. (Pubitemid 38030301)
26. Corcoran LJ, Mitchison TJ, Liu Q. A novel action of histone deacetylase inhibitors in a protein aggresome disease model. Curr Biol 2004;14:488-92. (Pubitemid 38431283)
27. Sandor V, Robbins AR, Robey R, Myers T, Sausville E, Bates SE, et al. FR901228 causes mitotic arrest but does not alter microtubule polymerization. Anticancer Drugs 2000;11:445-54.
28. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002;417:455-8. (Pubitemid 34563539)
29. Johnston JA, Illing ME, Kopito RR. Cytoplasmic dynein/dynactin mediates the assembly of aggresomes. Cell Motil Cytoskeleton 2002;53:26-38. (Pubitemid 34984442)
30. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 2000;10:524-30.
31. Fortun J, Dunn WA Jr, Joy S, Li J, Notterpek L. Emerging role for autophagy in the removal of aggresomes in Schwann cells. J Neurosci 2003;23:10672-80. (Pubitemid 37485281)
32. Iwata A, Christianson JC, Bucci M, Ellerby LM, Nukina N, Forno LS, et al. Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. Proc Natl Acad Sci U S A 2005;102:13135-40. (Pubitemid 41324991)
33. Chin LS, Olzmann JA, Li L. Parkin-mediated ubiquitin signalling in aggresome formation and autophagy. Biochem Soc Trans 2010;38:144-9.
34. Lukacs GL,MohamedA, Kartner N, Chang XB, Riordan JR, Grinstein S. Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. EMBO J 1994;13:6076-86.
35. Ward CL, Kopito RR. Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. J Biol Chem 1994;269:25710-8.
36. Loo TW, Clarke DM. Prolonged association of temperature-sensitive mutants of human P-glycoprotein with calnexin during biogenesis. J Biol Chem 1994;269:28683-9.
37. Hutt DM, Herman D, Rodrigues AP, Noel S, Pilewski JM, Matteson J, et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol 2010;6:25-33.
38. Riley NE, Bardag-Gorce F, Montgomery RO, Li J, Lungo W, Lue YH, et al. Microtubules are required for cytokeratin aggresome (Mallory body) formation in hepatocytes: an in vitro study. Exp Mol Pathol 2003;74:173-9. (Pubitemid 36438666)
39. Kim JY, Shen S, Dietz K, He Y, Howell O, Reynolds R, et al. HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat Neurosci 2010;13:180-9.
40. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K Jr, et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006;66:3773-81.
41. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-72.